Company news

AstraZeneca PLC news

Latest news releases, newest first. Pick a year for every news release, call and deck from that year.

View company

Brilinta obtains additional US approval

June 1, 2020

Imfinzi sustained overall survival in CASPIAN

May 29, 2020

Enhertu DESTINY-Gastric01 results from ASCO 2020

May 29, 2020

Tagrisso unprecedented adjuvant lung cancer data

May 29, 2020

Enhertu US orphan designation in gastric cancer

May 22, 2020

AstraZeneca advances response to COVID-19 outbreak

May 21, 2020

Lynparza approved in the US for prostate cancer

May 20, 2020

Enhertu US Breakthrough status for lung cancer

May 18, 2020

Bevespi Aerosphere approved in China for COPD

May 18, 2020

Lynparza gets broader US ovarian cancer approval

May 11, 2020

Enhertu designated gastric cancer BTD

May 11, 2020

Brazikumab rights recovered by AstraZeneca

May 11, 2020

Farxiga approved by FDA for heart failure (HFrEF)

May 6, 2020

AZN: first-quarter 2020 results

April 29, 2020

Lynparza shows overall survival in prostate cancer

April 24, 2020

Changes to arrangements for AGM

April 17, 2020

Tagrisso adjuvant trial overwhelmingly positive

April 14, 2020

Koselugo (selumetinib) approved in the US for NF1

April 14, 2020

AstraZeneca divestment of Movantik completed

April 2, 2020

Imfinzi approved in US for small cell lung cancer

March 30, 2020

Farxiga CKD trial early stop for positive efficacy

March 30, 2020

Lokelma approved in Japan for hyperkalaemia

March 26, 2020

Lynparza granted orphan drug designation in Japan

March 19, 2020

Imfinzi confirmed overall survival in CASPIAN

March 17, 2020

Update on Phase III GY004 trial for cediranib

March 12, 2020

Update on Phase III DANUBE trial in bladder cancer

March 6, 2020

Divestment of hypertension medicines completed

March 2, 2020

AstraZeneca divests global rights to Movantik

February 25, 2020

AZN: Full-year and Q4 2019 results

February 14, 2020

Enhertu Phase II trial met primary endpoint

January 27, 2020

Brilinta met primary endpoint in stroke trial

January 27, 2020

AstraZeneca to recover brazikumab (MEDI2070)

January 27, 2020

AstraZeneca divests hypertension medicines

January 27, 2020

Imfinzi, tremelimumab granted ODD in liver cancer

January 20, 2020

FDA grants Lynparza Priority Review for PROfound

January 20, 2020

Lynparza granted FDA Priority Review for PAOLA-1

January 13, 2020

Update on Epanova Phase III STRENGTH trial

January 13, 2020

Farxiga granted FDA heart failure Priority Review

January 6, 2020

Lokelma approved in China for hyperkalaemia

January 6, 2020

US FDA approved Lynparza for pancreatic cancer

December 30, 2019

Triple-combination approved in China for COPD

December 23, 2019

Enhertu (trastuzumab deruxtecan) approved in US

December 23, 2019

AstraZeneca divests rights to Arimidex and Casodex

December 20, 2019

FDA panel backs Lynparza use for pancreatic cancer

December 17, 2019

Seroquel rights agreement complete: Europe, Russia

December 16, 2019

Imfinzi approved in China for Stage III NSCLC

December 12, 2019

Trastuzumab deruxtecan achieves ORR of 60.9%

December 11, 2019

Lynparza approved in China for 1L BRCAm ovarian

December 5, 2019

AstraZeneca divests Seroquel rights: US and Canada

December 3, 2019

Imfinzi granted FDA Priority Review for SCLC

November 29, 2019

← Newer news releases · Older news releases →

Calls

The 5 newest of 16 calls. Every call is listed under its year.

Decks

The 5 newest of 249 decks. Every deck is listed under its year.